Mark S. Talamonti

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a multicentre study of four European psoriasis cohorts

M. Coenen, J. Lambert, M. Hakobjan, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis.

M. Talamonti, J. Tward, W. Small, 2011, International journal of radiation oncology, biology, physics.

Role of the HLA‐C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients

J. Lambert, A. Costanzo, E. D. De Jong, 2017, The British journal of dermatology.

Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292).

P. Catalano, A. Benson, M. Talamonti, 2011, International journal of radiation oncology, biology, physics.

Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab

A. Orlandi, A. Martini, I. Ceccherini, 2019, Pediatric Rheumatology.

Expression of Cell Adhesion Molecules, CD44s and E-Cadherin, and Microvessel Density in Carcinoid Tumors

M. Talamonti, M. Rao, Y. Gong, 2002, Modern Pathology.